Stocks and Investing
Stocks and Investing
Thu, July 7, 2022
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
Wed, July 6, 2022
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
Neena Bitritto-Garg Maintained (AMLX) at Strong Buy with Increased Target to $37 on, Jul 6th, 2022
Neena Bitritto-Garg of Citigroup, Maintained "Amylyx Pharmaceuticals, Inc." (AMLX) at Strong Buy with Increased Target from $33 to $37 on, Jul 6th, 2022.
Neena has made no other calls on AMLX in the last 4 months.
There are 2 other peers that have a rating on AMLX. Out of the 2 peers that are also analyzing AMLX, 1 agrees with Neena's Rating of Hold. Following is the relevant analyst calls for the last 4 months
- Chris Shibutani of "Goldman Sachs" Downgraded from Strong Buy to Hold and Decreased Target to $10 on, Friday, April 1st, 2022
This is the rating of the analyst that currently disagrees with Neena
- Marc Goodman of "SVB Leerink" Maintained at Buy with Decreased Target to $31 on, Thursday, March 31st, 2022
Contributing Sources